MEDNAX Inc (MD) Stake Boosted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its holdings in shares of MEDNAX Inc (NYSE:MD) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,590 shares of the company’s stock after purchasing an additional 3,059 shares during the period. Envestnet Asset Management Inc. owned approximately 0.05% of MEDNAX worth $2,650,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MD. Delta Capital Management LLC bought a new position in shares of MEDNAX during the 4th quarter valued at about $227,000. Brown Advisory Inc. bought a new position in shares of MEDNAX during the 4th quarter valued at about $231,000. YHB Investment Advisors Inc. bought a new position in shares of MEDNAX during the 4th quarter valued at about $235,000. Shelton Capital Management bought a new position in shares of MEDNAX during the 4th quarter valued at about $245,000. Finally, Trexquant Investment LP bought a new position in shares of MEDNAX during the 3rd quarter valued at about $250,000. Institutional investors and hedge funds own 98.53% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total value of $175,050.00. Following the sale, the insider now owns 39,716 shares in the company, valued at approximately $2,317,428.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

MD has been the topic of several recent analyst reports. Piper Jaffray initiated coverage on MEDNAX in a report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price objective on the stock. SunTrust Banks set a $55.00 price objective on MEDNAX and gave the company a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research upgraded MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a report on Tuesday, January 23rd. Stifel Nicolaus reiterated a “hold” rating and set a $56.00 price objective on shares of MEDNAX in a report on Wednesday, January 24th. Finally, Mizuho set a $49.00 price objective on MEDNAX and gave the company a “hold” rating in a report on Wednesday, January 24th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $55.69.

NYSE MD opened at $54.67 on Friday. The company has a market capitalization of $5,178.45, a price-to-earnings ratio of 17.36, a PEG ratio of 1.37 and a beta of 0.23. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. MEDNAX Inc has a 52 week low of $40.56 and a 52 week high of $68.55.

MEDNAX (NYSE:MD) last released its earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.04. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.00 EPS. equities analysts expect that MEDNAX Inc will post 4.02 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3337352/mednax-inc-md-stake-boosted-by-envestnet-asset-management-inc.html.

MEDNAX Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ironwood Pharmaceuticals  Downgraded by Zacks Investment Research
Ironwood Pharmaceuticals Downgraded by Zacks Investment Research
Pentair  Stock Rating Lowered by Zacks Investment Research
Pentair Stock Rating Lowered by Zacks Investment Research
Contrasting Foreign Trade Bank of Latin America  & Its Peers
Contrasting Foreign Trade Bank of Latin America & Its Peers
Contrasting National Presto Industries  and Vista Outdoor
Contrasting National Presto Industries and Vista Outdoor
Financial Survey: Lincoln Electric  versus Spx Flow
Financial Survey: Lincoln Electric versus Spx Flow
J.Jill  Downgraded by ValuEngine
J.Jill Downgraded by ValuEngine


© 2006-2018 Ticker Report. Google+.